Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3839871 | 0.94 | CCR5 (0.55) | CCR5MEN1KMT2AGPR119USP30 | |
| SCHEMBL3837667 | 0.93 | MEN1 (0.61) | CCR5MEN1KMT2AGPR119USP30 | |
| SCHEMBL18263756 | 0.86 | MEN1 (0.60) | MEN1KMT2AGPR119USP30KDM4E | |
| SCHEMBL3842743 | 0.86 | MEN1 (0.57) | MEN1KMT2AGPR119USP30JAK2 | |
| SCHEMBL18263728 | 0.86 | MEN1 (0.72) | MEN1KMT2AGPR119USP30JAK2 | |
| SCHEMBL18263761 | 0.83 | MEN1 (0.60) | CCR5MEN1KMT2AGPR119USP30 | |
| SCHEMBL2792425 | 0.81 | MEN1 (0.60) | MEN1KMT2AGPR119USP30JAK2 | |
| SCHEMBL3844128 | 0.81 | CCR5 (0.69) | CCR5 | |
| SCHEMBL4386525 | 0.81 | GPR119 (0.56) | CCR5MEN1KMT2AGPR119USP30 | |
| SCHEMBL4498115 | 0.80 | OPRD1 (0.62) | MEN1KMT2AGPR119USP30OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379504-B1 | BIPIPERIDINYL-DERIVATIVES AND THEIR USE AS CHEMOKINE RECEPTORS INHIBITORS | NOVARTIS PHARMA GMBH (AT) | 2009-10-28 | — | — | EP | disclosed |
| US-20040142920-A1 | Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors | NOVARTIS | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142920-A1 | Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors | CCR5, CCR2, CXCR3 | CCR5 1/4885MEN1 4870/4885KMT2A 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.